share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改注册声明表
美股SEC公告 ·  04/22 12:38
Moomoo AI 已提取核心信息
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.
180 Life Sciences Corp. 已于2024年4月19日向美国证券交易委员会（SEC）提交了对S-1表格注册声明的生效后修正案。该修正案涉及公司先前发行的认股权证，允许持有人购买公司普通股。认股权证的行使价为每股3.23美元，有效期至2029年2月16日。该文件确保注册声明中的信息是最新的，并更新了生效后第1号修正案所附的招股说明书。注册声明涵盖2023年8月的242,915份普通认股权证及其行使后可发行的普通股。没有根据该修正案注册其他证券，所有适用的注册费均已在最初提交时支付。该公司的普通股在纳斯达克资本市场上交易，股票代码为 “ATNF”。
180 Life Sciences Corp. 已于2024年4月19日向美国证券交易委员会（SEC）提交了对S-1表格注册声明的生效后修正案。该修正案涉及公司先前发行的认股权证，允许持有人购买公司普通股。认股权证的行使价为每股3.23美元，有效期至2029年2月16日。该文件确保注册声明中的信息是最新的，并更新了生效后第1号修正案所附的招股说明书。注册声明涵盖2023年8月的242,915份普通认股权证及其行使后可发行的普通股。没有根据该修正案注册其他证券，所有适用的注册费均已在最初提交时支付。该公司的普通股在纳斯达克资本市场上交易，股票代码为 “ATNF”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息